Portal de investigación
Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer.
Fecha de publicación:
Fecha Ahead of Print:
Autores de INCLIVA
Grupos y Plataformas de I+D+i
Abstract
Most clinical practice guidelines recommend a selective approach for rectal cancer after clinical staging. In low-risk patients, upfront surgery may be an appropriate option. However, in patients with MRI-defined high-risk features such as extramural vascular invasion, multiple nodal involvement or T4 and/or tumors close to or invading the mesorectal fascia, a more intensive preoperative approach is recommended, which may include neoadjuvant or preoperative chemotherapy. The potential benefits include better compliance than postoperative chemotherapy, a higher pathological complete remission rate, which facilitates a non-surgical approach, and earlier treatment of micrometastatic disease with improved disease-free survival compared to standard preoperative chemoradiation or short-course radiation. Two recently reported phase III randomized trials, RAPIDO and PRODIGE 23, show that adding neoadjuvant chemotherapy to either standard short-course radiation or standard long-course chemoradiation in locally advanced rectal cancer patients reduces the risk of metastasis and significantly prolongs disease-related treatment failure and disease-free survival. This review discusses these potentially practice-changing trials and how they may affect our current understanding of treating locally advanced rectal cancers.
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
Datos de la publicación
- ISSN/ISSNe:
- 2072-6694, 2072-6694
- Tipo:
- Article
- Páginas:
- -
- PubMed:
- 33287114
Cancers MDPI
Citas Recibidas en Web of Science: 40
Documentos
Filiaciones
Keywords
- high-risk locally advanced rectal cancer; total neoadjuvant treatment; watch and wait strategy
Financiación
Proyectos y Estudios Clínicos
Enfermedad mínima residual en cánceres colorrectales de alto riesgo resecados. Valor de las biopsias líquidas en el seguimiento y análisis de la heterogeneidad tumoral.
Investigador Principal: ANDRÉS CERVANTES RUIPEREZ
PI15/02180 . INSTITUTO SALUD CARLOS III . 2016
Medicina personalizada en pacientes con cáncer colorrectal localizado: abordaje multiómico de la Enfermedad Mínima Residual en biopsia líquida y modelos de organoides
Investigador Principal: ANDRÉS CERVANTES RUIPEREZ
PI18/01909 . INSTITUTO SALUD CARLOS III . 2019
Cita
Papaccio F,Rosello S,Huerta M,Gambardella V,Tarazona N,Fleitas T,Roda D,Cervantes A. Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer. Cancers. 2020. 12. (12):3611. IF:6,639. (1).
Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer. Papaccio F, Rosello S, Huerta M, Gambardella V, Tarazona N, Fleitas T, Roda D et al. Cancers. 2020 diciembre 03. 12 (12):DOI:10.3390/cancers12123611. PMID:33287114.
